OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Wang on Unique Properties of KTE-X19 in Relapsed/Refractory MCL

May 5th 2020

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Wang-Gillam on Next Steps With Defactinib Combo in Pancreatic Ductal Adenocarcinoma

May 5th 2020

Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.

Dr. Oh on Challenges With Developing Novel Targeted Agents in Prostate Cancer

May 5th 2020

William K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.

Dr. Lopategui on the Evolution of Molecular Testing in NSCLC

May 5th 2020

Jean Lopategui, MD, discusses the evolution of molecular testing in non–small cell lung cancer.

Dr. Tolaney on Remaining Questions With CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

May 5th 2020

Sara M. Tolaney, MD, MPH, discusses remaining questions with CDK4/6 inhibitors in hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr. Coleman on Recent Advances and Remaining Questions in Ovarian Cancer

May 5th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses recent advances made in the treatment of patients with ovarian cancer and remaining questions regarding the role of immunotherapy.

Dr. Carbone on Acquired Resistance to Osimertinib in NSCLC

May 5th 2020

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

Dr. Hwang on the Addition of Radium-223 to Abiraterone Acetate and Prednisone in mCRPC

May 5th 2020

Clara Hwang, MD, discusses the phase 3 ERA-223 trial evaluating the addition of radium-223 dichloride to abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and bone metastases.

Dr. Williams on NLR as a Prognostic Biomarker in NSCLC

May 5th 2020

Terence M. Williams, MD, PhD, discusses research examining a serum biomarker, neutrophil-to-lymphocyte ratio, in non–small cell lung cancer.

Dr. Desai Sheds Light on COVID-19 Risk Among Patients With Cancer

May 5th 2020

Aakash Desai, MD, MPH, provides additional insight into his research on COVID-19 risk and patients with cancer and shed light on how institutions are taking action against the virus.

Dr. Favret on the Evolution of Treatment in HER2+ Breast Cancer

May 4th 2020

Anne Favret, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Dr. Michaelis on the Role of Interferon in MPNs

May 4th 2020

Laura C. Michaelis, MD, discusses the role of interferon in myeloproliferative neoplasms.

Dr. Miklos on Anticipated Sequencing Challenges With KTE-X19 in MCL

May 4th 2020

David Miklos, MD, discusses anticipated sequencing challenges with the investigational CAR T-cell therapy KTE-X19 in mantle cell lymphoma.

Dr. Yee on the Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma

May 4th 2020

Andrew Yee, MD, discusses the role of carfilzomib in relapsed/refractory multiple myeloma.

Dr. Saba on the Impact of COVID-19 on Telehealth in Head and Neck Cancer

May 4th 2020

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses the impact of the coronavirus disease 2019 (COVID-19) on telehealth in head and neck cancer.

Dr. Voorhees on the Effectiveness of Idecabtagene Vicleucel in Multiple Myeloma

May 2nd 2020

Peter Voorhees, MD, discusses the evolution of idecabtagene vicleucel (ide-cel; bb2121) in the phase 2 KarMMa study in relapsed/refractory multiple myeloma.

Dr. Bekaii-Saab on Moving Metastatic Treatment Strategies to the Adjuvant Setting in CRC

May 2nd 2020

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

Dr. Awan on Remaining Questions With BTK Inhibitors and Anti-CD20 Combos in CLL

May 2nd 2020

Farrukh Awan, MD, discusses remaining questions regarding the use of BTK inhibitors and CD20-directed monoclonal antibodies in chronic lymphocytic leukemia.

Dr. Hidalgo Medina on the Rationale for Using Patient-Derived Organoids in Pancreatic Cancer

May 2nd 2020

Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses that rationale for using patient-derived organoids (PDOs) in pancreatic cancer.

Dr. Wright on Proton Versus Photon Radiotherapy in Breast Cancer

May 2nd 2020

Jean Wright, MD, discusses proton versus photon radiotherapy in breast cancer.